GlaxoSmithKline Probes Botox Marketing in China

Published: Jul 08, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GlaxoSmithKline said on Monday it was investigating new allegations that its staff had used improper tactics to market Botox in China, but had so far found no evidence of bribery or corruption. The move follows a claim that GSK staff allegedly handed doctors cash and other rewards for prescribing Botox treatment, which the British group sells in China under an agreement with patent-holder Allergan. The latest allegations against GSK, which is already under investigation by Chinese police for unspecified "economic crimes", were first reported by the Wall Street Journal. The newspaper said internal documents and email showed GSK's China sales staff were also apparently instructed to use their personal email addresses to discuss marketing strategies related to Botox.

Help employers find you! Check out all the jobs and post your resume.

Back to news